Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

Susceptibility to a clinically significant drug hypersensitivity syndrome associated with abacavir use seems to have a strong genetic component. We have previously shown that the presence of HLA-B*5701 strongly predicts abacavir hypersensitivity and have identified a potential susceptibility locus within a 300-kb region between the MEGT1 and C4A6 loci in the central MHC. We now report the results of fine recombinant genetic mapping in an expanded patient population of 248 consecutive, fully ascertained, abacavir-exposed individuals in the Western Australian HIV Cohort Study, in which 18 cases of definite abacavir hypersensitivity (7.3%) and 230 tolerant controls were identified. Haplotype mapping within patients with allelic markers of the 57.1 ancestral haplotype suggests a susceptibility locus within the 14-kb Hsp70 gene cluster. HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001). A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001). Individuals with abacavir hypersensitivity demonstrated increased monocyte tumor necrosis factor expression in response to ex vivo abacavir stimulation, which was abrogated with CD8+ T cell depletion. These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity, which is likely to be mediated by an HLA-B*5701-restricted immune response to abacavir.

[1]  J. Fabre,et al.  Reasons for Early Abacavir Discontinuation in HIV-Infected Patients , 2003, The Annals of pharmacotherapy.

[2]  P. Srivastava,et al.  Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. , 1999, Journal of immunology.

[3]  Tariq Ahmad,et al.  Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. , 2003, Human molecular genetics.

[4]  P. Demoly,et al.  Hypersensitivity Related to Abacavir in Two Members of a Family , 2001, The Annals of pharmacotherapy.

[5]  J. Sambrook,et al.  Common and divergent peptide binding specificities of hsp70 molecular chaperones. , 1994, The Journal of biological chemistry.

[6]  S. Knowles,et al.  Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. , 2002, AIDS.

[7]  M. Britschgi,et al.  Molecular aspects of drug recognition by specific T cells. , 2003, Current drug targets.

[8]  R. Binder,et al.  Heat Shock Protein-chaperoned Peptides but Not Free Peptides Introduced into the Cytosol Are Presented Efficiently by Major Histocompatibility Complex I Molecules* , 2001, The Journal of Biological Chemistry.

[9]  Pramod K. Srivastava,et al.  Heat Shock Protein–Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity , 1997, The Journal of experimental medicine.

[10]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[11]  S. Valitutti,et al.  HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. , 1998, The Journal of clinical investigation.

[12]  F. Christiansen,et al.  An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes , 1992, Immunogenetics.

[13]  David Nolan,et al.  Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? , 2003, Journal of HIV therapy.

[14]  M. Pirmohamed,et al.  Metabolic activation in drug allergies. , 2001, Toxicology.

[15]  J. Walsh,et al.  The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. , 2002, Chemico-biological interactions.

[16]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[17]  D. Vittecoq,et al.  Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. , 1999, AIDS.

[18]  S. H. van der Burg,et al.  Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. , 1998, The Journal of general virology.

[19]  P. Srivastava,et al.  Heat shock proteins transfer peptides during antigen processing and CTL priming , 2004, Immunogenetics.

[20]  B. Haldane.  THE ESTIMATION AND SIGNIFICANCE OF THE LOGARITHM OF A RATIO OF FREQUENCIES , 1956, Annals of human genetics.

[21]  P. Ostermann,et al.  Heat shock protein 70 genotypes HSPA1B and HSPA1L influence cytokine concentrations and interfere with outcome after major injury* , 2003, Critical care medicine.

[22]  Ronald E. Bontrop,et al.  Immunogenetics , 2005, Genes and Immunity.

[23]  J. Rothman,et al.  Receptor-Mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways , 2000, The Journal of experimental medicine.

[24]  O. Naderer,et al.  Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. , 2001, Clinical therapeutics.

[25]  S. Kharb.  Toxicology , 1936 .

[26]  C. Milner,et al.  Structure and expression of the three MHC-linked HSP70 genes , 2004, Immunogenetics.

[27]  G. Dahlberg,et al.  Genetics of human populations. , 1948, Advances in genetics.

[28]  Isma'il ibn Ali al-Sadiq.  AIDS , 1986, The Lancet.

[29]  Paola Sebastiani,et al.  Minimal haplotype tagging , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Yamazaki,et al.  Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Price,et al.  Polymorphisms in lymphotoxin alpha and CD14 genes influence TNFα production induced by Gram-positive and Gram-negative bacteria , 2003, Genes and Immunity.

[32]  M. Pirmohamed,et al.  Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T Cells from Allergic Individuals1 , 2000, The Journal of Immunology.

[33]  S. Hetherington,et al.  Risk factor analysis of hypersensitivity reactions to abacavir. , 2002, Clinical therapeutics.

[34]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[35]  Hong Wang,et al.  High-resolution solution structure of the 18 kDa substrate-binding domain of the mammalian chaperone protein Hsc70. , 1999, Journal of molecular biology.

[36]  D. Thorburn,et al.  Epidemiological risk factors for hypersensitivity reactions to abacavir * , 2003, HIV medicine.